Mycenax Biotech Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	216.32	224.55	269.57	519.27	1,323	286.93
Short-Term Investments	1.2	-	7.3	148.42	16.12	-
Cash & Short-Term Investments	217.52	224.55	276.87	667.69	1,339	286.93
Cash Growth	-20.24%	-18.90%	-58.53%	-50.15%	366.84%	-1.45%
Accounts Receivable	170.07	130.88	140.74	58.53	81.32	320.84
Other Receivables	8.68	8.12	7.73	4.69	3.09	11.33
Receivables	178.74	139	148.47	63.22	84.41	332.17
Inventory	171.85	132.89	64.94	112.33	246.72	173.3
Prepaid Expenses	58.91	57.49	71.45	83.25	103.22	89.28
Other Current Assets	221.45	222.1	174.66	171.53	149.95	15.73
Total Current Assets	848.48	776.02	736.38	1,098	1,924	897.41
Property, Plant & Equipment	2,088	1,577	1,705	1,847	1,978	1,351
Long-Term Investments	149.39	155.56	177.87	190.81	199.51	109.59
Goodwill	-	23.92	23.92	23.92	23.92	23.92
Other Intangible Assets	44.93	17.21	12.34	18.98	25.93	33.71
Long-Term Deferred Tax Assets	104.93	101.06	98.6	95.49	89.72	81.11
Other Long-Term Assets	107.99	610.8	614.67	495.85	211.93	642.46
Total Assets	3,343	3,261	3,368	3,770	4,453	3,139
Accounts Payable	57.86	77.47	34.63	44.05	52.52	54.68
Accrued Expenses	-	102.96	98.05	112.32	104.21	96.4
Short-Term Debt	450	280	-	-	100	50
Current Portion of Long-Term Debt	197.88	196.55	168.08	125.92	105.88	15.6
Current Portion of Leases	39.53	39.21	31.92	30.57	37.28	28.59
Current Unearned Revenue	475.01	361.69	230.85	187.28	142.28	152.12
Other Current Liabilities	139.06	48.19	97.97	253.28	92.57	142.69
Total Current Liabilities	1,359	1,106	661.5	753.42	634.73	540.07
Long-Term Debt	384.53	433.67	611.37	530.4	656.32	474.4
Long-Term Leases	112.78	122.46	72.04	39.39	56.37	176.06
Long-Term Deferred Tax Liabilities	-	-	-	-	-	3.75
Other Long-Term Liabilities	-	-	-	-	-	38.07
Total Liabilities	1,857	1,662	1,345	1,323	1,347	1,232
Common Stock	2,073	2,072	2,070	2,059	2,053	1,533
Additional Paid-In Capital	73.84	67.32	421.11	1,074	1,468	576.95
Retained Earnings	-657.62	-540.63	-466.91	-682.64	-406.83	-254.34
Comprehensive Income & Other	-1.97	0.04	-0.79	-3.32	-8.8	50.72
Shareholders' Equity	1,487	1,599	2,023	2,447	3,106	1,907
Total Liabilities & Equity	3,343	3,261	3,368	3,770	4,453	3,139
Total Debt	1,185	1,072	883.39	726.28	955.85	744.64
Net Cash (Debt)	-967.21	-847.35	-606.53	-58.59	383.63	-457.72
Net Cash Per Share	-4.67	-4.09	-2.94	-0.29	2.32	-3.08
Filing Date Shares Outstanding	207.23	207.23	207.01	205.89	205.31	153.33
Total Common Shares Outstanding	207.23	207.23	207.01	205.89	205.31	153.33
Working Capital	-510.87	-330.04	74.89	344.59	1,289	357.34
Book Value Per Share	7.17	7.72	9.77	11.89	15.13	12.43
Tangible Book Value	1,442	1,558	1,987	2,404	3,056	1,849
Tangible Book Value Per Share	6.96	7.52	9.60	11.68	14.88	12.06
Buildings	-	819.36	792.86	792.86	791.68	-
Machinery	-	1,597	1,594	1,603	1,575	837.57
Construction In Progress	-	165.54	158.09	106.85	3.35	624.35
Leasehold Improvements	-	325.48	325.53	317.34	307.77	276.23